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t has sometimes been observed that if there are many solutions to a problem, then it is probable that none is exactly correct. Such is the circumstance for young, adult-sized patients facing surgical aortic valve replacement (AVR). For their much younger and smaller counterparts, in whom somatic growth is incomplete, the pulmonary autograft (Ross procedure) is certainly the correct solution. 1 At the other end of the age spectrum, for patients >70 years of age, a stented bioprosthesis is virtually always the best choice unless high surgical risk would favor transcatheter AVR. 2 For patients <60 years of age, a mechanical prosthesis is appropriate, although current American College of Cardiology/American Heart Association guidelines of the management of patients with valvular heart disease include the following hedge: "A bioprosthesis is recommended in patients of any age for whom anticoagulant therapy is contraindicated, cannot be managed appropriately, or is not desired."
1 Therein lies the rub: Virtually no young adult desires anticoagulation, and adherence to complex medication regimens in this age group is notoriously poor, rendering the "appropriate" management of vitamin K antagonist (VKA) medication dosage problematic. 3 Furthermore, a substantial number of young, adult-sized patients facing AVR are female and may wish to avoid VKA during childbearing years, despite recent reports describing favorable outcomes in women with carefully supervised VKA-based anticoagulation during pregnancy. 4 Thus, for young, adult-sized patients (and their parents), the contemplation of which valve is the best, or least worst, choice is based on multiple factors, as shown in the Table, with the final selection based on the combination of risk assessment and lifestyle preferences unique to each young patient. (For the sake of completeness, the Table includes the option of stentless bioprostheses, either allograft or xenograft, although they are rarely used except in unusual forms of endocarditis and extremely small aortic root dimension that would cause severe patient-prosthetic mismatch with conventional AVR.) In this issue of Circulation, Saleeb et al 
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The report exemplifies the complexity of decision making for this patient population. In contrast, the choice of prosthesis for older adults is simple: If the patient is elderly or middle-aged but cannot or will not take VKA, a bioprosthesis is elected and implanted via conventional open-heart surgery or by transcatheter AVR. If the patient is young, able, and willing to take VKA, a mechanical prosthesis is preferred. For the young adult, additional factors beyond age such as childbearing status, lifestyle and occupational priorities, other cardiac issues (such as coexistent right ventricular to pulmonary artery conduits), multiple prior operations, and connective tissue disease may merit consideration. The calculations for a 20-year-old patient facing 4 or 5 additional aortic valve interventions are quite different from those for his or her grandparent who would likely face at most 1 additional procedure. For the latter patient, the prospect of a valve-in-valve transcatheter AVR 15 years hence is a very reasonable intervention after an initial surgical AVR with a bioprosthesis. 6 For the 20-year-old patient whose bioprosthesis, under the best of circumstances, will have a much shorter effective life span, the prospect of a transcatheter AVR at 28 years of age is likely of little solace, given the requirement for several subsequent AVRs. When it comes to choosing an aortic valve prosthesis, youth brings complexity, and the implications of any choice are amplified by the much, much longer period of postoperative hazard.
Among the most important aspects of this report is its genesis: The index case was detected at an autopsy performed after a sudden death during a gastrointestinal illness. The lamentably low rate of autopsies has been discussed extensively, 7 and certainly no practitioner would have difficulty imagining that an autopsy might not have been done at his or her own institution in a similar setting. Although the exact details of communication between pathologist and cardiologist that led to this report are not spelled out in great detail, it is evident that a meticulous postmortem examination was the sine qua non. The recognition of the importance of the pathological findings was also crucial; a cardiologist or several cardiologists contemplated a severely degenerated and obstructed valve in the context of a minimally abnormal echocardiogram a few months earlier. Rather than shrugging off these 2 pieces of data as a singular event, the authors demonstrated the exemplary response of digging deeper and further. This led to "intensified echocardiographic surveillance," which in turn led to the detection of a systematic problem. The process is an example of the best kind of medical detective work, and it should remind us all of the value of autopsy and careful examination of the details of bad outcomes. Recognition that a sentinel event is indeed sentinel is the first step.
Another important development presented in this report is a detailed protocol for describing bioprosthetic valve dysfunction. The methodology presented by the authors mandates the assessment of the mobility of each bioprosthetic leaflet with assignment of a score based on the degree of restriction and the number of leaflets involved. Leaflet thickness is also quantified on the basis of the degree of thickening and the number of leaflets that are thickened. More standard measures of valve function, maximal instantaneous gradient and mean Doppler gradient, are also reported. Taken as a whole, this approach permits more sophisticated and quantitative surveillance than is possible when the echocardiographic report includes only valve gradients and qualitative descriptions of valve morphology, as is typical in this setting. The approach the authors have described may have much broader application. For example, this technique would be very helpful in assessing the inevitable deterioration of all bioprosthetic valves (porcine, pericardial, allograft, bovine jugular vein, etc), regardless of cardiac position.
Perhaps the most important lesson in this report is the demonstration that not all prosthetic heart valves are alike. To be sure, heart valve manufacturers spend millions of dollars annually to convince the medical and surgical community that this is so. Each company and its representatives will produce, either on request or unbidden, wonderfully illustrated diagrams, operative photographs, multimedia presentations, and even publications by respected authors in respected journals, all attesting to the superiority of their product compared with the competition. Each new report or presentation describing the advantages of one device is shortly followed by a counterpoint from a competitor, pointing out flaws in the new report. The peer-reviewed literature and the company-sponsored material are so voluminous on behalf of each prosthesis that it becomes relatively easy to assume equivalence. As this report reminds us, in some cases, that assumption may be faulty.
On the topic of between-prosthesis difference, an obvious question raised by this report is whether the contrasting performance of the 2 pericardial valves could have been anticipated. In the ideal, medical decision making is guided by high-quality evidence derived from randomized, multicenter, prospective trials that are adequately powered to detect meaningful differences in effect or performance, have sufficient follow-up to detect late discriminant outcomes, and are performed in broadly representative populations. This report demonstrates the real world of valve literature: Most bioprosthetic valve studies are single-center, nonrandomized trials with relatively short follow-up that are conducted in middle-aged and elderly patients. Studies that examine the impact of age on outcomes include very few patients <50 years of age [8] [9] [10] and tend to examine differences between age strata within an elderly population. Only a tiny fraction of the published experience includes patients <30 years of age. Guidance for valve choice in the young therefore represents extrapolation from large amounts of data in the middle-aged and elderly and very little actual data drawn from the population of interest. [11] [12] [13] Nonetheless, even with these caveats in mind, there are suggestions that the Mitroflow valve is particularly prone to relatively early calcification, even in the elderly. [14] [15] [16] Indeed, in a recent state-of-the-art review, Rahimtoola 11 suggested that the Mitroflow is prone to "very early" structural valve deterioration, comparing it unfavorably with the Edwards pericardial valve.
The mechanism of "accelerated degeneration" in the Mitroflow valves in the present report is certainly related to the deposition of calcium salts in the leaflets, or calcification, as demonstrated in the figures in the report. This mode of failure has long been recognized as the Achilles' heel of glutaraldehyde-preserved bioprostheses. 12, 17 Calcification is almost certainly related to phospholipid and aldehyde moieties, which remain in the biological material after glutaraldehyde fixation. 18 Demonstration of the particularly high "calcification potential" of the Mitroflow prosthesis was provided a decade ago in a rodent subcutaneous model. 19 The Mitroflow had among the highest phospholipid content before implantation and highest calcium content after explantation. Attempts to slow calcium deposition have been ongoing for many years, and some manufacturers offer valves that have been treated with proprietary antimineralization processes. One of the valves in the report (the Magna/Magna Ease) was treated with Thermafix (Edwards Lifesciences), a proprietary antimineralization technique. In contrast, the Mitroflow valve is not treated with antimineralization. A recent retrospective study conducted in elderly patients (mean age, 74 years) showed lack of antimineralization to be in important risk factor for early bioprosthetic valve deterioration. 20 In conclusion, the present report is a cautionary tale for those who care for young adults with aortic valve disease. The version of the Mitroflow valve available in the United States should not be implanted in young adults in the future. For those patients who have already had the valve implanted, enhanced surveillance, as described in the present report, should be initiated immediately if it is not already underway.
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